Back to Search Start Over

Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme : early findings of the ANRS 12249 TasP trial in rural South Africa

Authors :
François Dabis
Sylvie Boyer
Nuala McGrath
Camelia Protopopescu
Bruno Spire
Joanna Orne-Gliemann
Andréa Gosset
Nonhlanhla Okesola
Collins Iwuji
Mélanie Plazy
Deenan Pillay
Joseph Larmarange
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD)
Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN)
University College of London [London] (UCL)
Africa Centre for Health and Population Studies
University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN)-Medical Research Council of South Africa
Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA)
Epidémiologie et Biostatistique [Bordeaux]
Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Bordeaux population health (BPH)
Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Centre population et développement (CEPED - UMR_D 196)
Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)
The French National Agency for Aids and Viral Hepatitis Research (ANRS)
Research discussed in this publication has been co-funded by the International Initiative for Impact Evaluation, Inc. (3ie) with support from the Bill & Melinda Gates Foundation.
The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) has co-funded the trial
The trial is conducted with the support of Merck & Co. Inc and Gilead Sciences that provided the Atripla® drug supply
The Africa Centre for Population Health receives core funding from the Wellcome Trust, which provides the platform for the population- and clinic-based research at the Centre.
Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)
University of KwaZulu-Natal (UKZN)
University of KwaZulu-Natal (UKZN)-Medical Research Council of South Africa
Lissalde, Claire
Source :
AIDS Care, AIDS Care, 2016, 28 (sup3), pp.39-51. ⟨10.1080/09540121.2016.1164808⟩, AIDS Care, Taylor & Francis (Routledge), 2016, 28 (sup3), pp.39-51. ⟨10.1080/09540121.2016.1164808⟩, AIDS care
Publication Year :
2016

Abstract

International audience; Prompt uptake of antiretroviral treatment (ART) is essential to ensure the success of universal test and treat (UTT) strategies to prevent HIV transmission in high-prevalence settings. We describe ART initiation rates and associated factors within an ongoing UTT cluster-randomized trial in rural South Africa. HIV-positive individuals were offered immediate ART in the intervention arm vs. national guidelines recommended initiation (CD4≤350 cells/mm(3)) in the control arm. We used data collected up to July 2015 among the ART-eligible individuals linked to TasP clinics before January 2015. ART initiation rates at one (M1), three (M3) and six months (M6) from baseline visit were described by cluster and CD4 count strata (cells/mm(3)) and other eligibility criteria: ≤100; 100-200; 200-350; CD4>350 with WHO stage 3/4 or pregnancy; CD4>350 without WHO stage 3/4 or pregnancy. A Cox model accounting for covariate effect changes over time was used to assess factors associated with ART initiation. The 514 participants had a median [interquartile range] follow-up duration of 1.08 [0.69; 2.07] months until ART initiation or last visit. ART initiation rates at M1 varied substantially (36.9% in the group CD4>350 without WHO stage 3/4 or pregnancy, and 55.2-71.8% in the three groups with CD4≤350) but less at M6 (from 85.3% in the first group to 96.1-98.3% in the three other groups). Factors associated with lower ART initiation at M1 were a higher CD4 count and attending clinics with both high patient load and higher cluster HIV prevalence. After M1, having a regular partner was the only factor associated with higher likelihood of ART initiation. These findings suggest good ART uptake within a UTT setting, even among individuals with high CD4 count. However, inadequate staffing and healthcare professional practices could result in prioritizing ART initiation in patients with the lowest CD4 counts.

Details

ISSN :
09540121 and 13600451
Database :
OpenAIRE
Journal :
AIDS Care, AIDS Care, 2016, 28 (sup3), pp.39-51. ⟨10.1080/09540121.2016.1164808⟩, AIDS Care, Taylor & Francis (Routledge), 2016, 28 (sup3), pp.39-51. ⟨10.1080/09540121.2016.1164808⟩, AIDS care
Accession number :
edsair.doi.dedup.....1843665473e93947615cdc66b72d06a7